Anakinra for the Treatment of Hemophagocytic Lymphohistiocytosis: 21 Cases

Clara Baverez 1,⁎, Maximilien Grall 2, Mathieu Gerfaud-Valentin 1, Sarah De Gail 3, Alexandre Belot 4,5,⁎, Thomas Perpoint 6, Emmanuelle Weber 1, Quitterie Reynaud 7,8, Pascal Sève 1,8, and Yvan Jamilloux 1,3

Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening cytokine storm syndrome. There are no definitive guidelines for the management of secondary HLH (sHLH). A recent report by a National Health Service (NHS) clinical panel has recommended anakinra as a treatment option. We aimed to analyse the efficacy and safety of anakinra for the treatment of all-cause sHLH. We conducted a multicentric retrospective study in two French University hospitals and included all patients who had a diagnosis of sHLH and who received anakinra. Among 21 patients (median age, 45 years), 13 were men. Anakinra was used as first-line therapy in 10 patients, and as monotherapy in 5 patients. We found that anakinra was effective in 19/21 patients (90.5%), with fever resolution in 19 patients (90.5%) within a median of 1.0 day (1, 2). At the Day 7 assessment, the mean CRP concentration decreased significantly (p < 0.001), as did the mean ferritin (p = 0.011). Anakinra was generally safe and well tolerated and was discontinued for side effects in only three patients (14.3%). Anakinra is an efficient and safe treatment to control sHLH of various causes. These data, together with the recent report of the NHS panel, call for the rapid conduct of prospective randomized clinical trials.

Keywords: anakinra; interleukin-1; hemophagocytic lymphohistiocytosis; adult onset Still’s disease; immunotherapy; cytokines; inflammatory mediators

1. Introduction

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening cytokine storm syndrome characterized by non-remitting fever, hepatosplenomegaly and cytopenia. HLH encompasses several conditions, with primary HLH (pHLH) being genetically determined, while secondary HLH (sHLH) may complicate infections, malignancies, immunodeficiencies or rheumatic diseases [1]. In the latter case, it most often occurs in the context of Still’s disease or systemic lupus erythematosus, and is termed macrophage activation syndrome. HLH results from an uncontrolled hyperinflammatory response, characterized by hyperferritinemia, elevated levels of proinflammatory cytokines (including IFN-γ, IL-1β, IL-6, IL-12, IL-18 and TNF) and hemophagocytosis [2].
Unlike pHLH [3], there are no single guidelines for the management of sHLH. The first reason is probably the lack of recognition of sHLH as a per se entity requiring specific treatment (i.e., as an aggravating condition), with the attention of physicians being focused on treating the underlying cause. The second reason is the heterogeneity (and sometimes co-existence) of the underlying aetiologies, some of which even make the use of immunosuppressive drugs counter-intuitive (infection, lymphoma). Finally, the diagnosis of sHLH can sometimes be missed or neglected due to the absence of sensitive and specific markers and validated diagnostic scores for all these situations.

In addition to treatment of the underlying condition, management of sHLH requires rapid suppression of the hyperinflammatory response. Steroids are usually the mainstay of initial immunosuppression. Etoposide is considered for refractory sHLH or in case of organ failure [4]. However, etoposide yields haematological toxicity and caution is advised in severe renal and liver impairment.

Despite the low-quality of evidence, the recombinant IL-1 receptor antagonist (IL-1Ra), anakinra, has recently been recommended by some authors [4,5] and an NHS clinical panel [6] as a second-line treatment for sHLH, after corticosteroid failure. This recommendation was based on single-centre retrospective case series of paediatric [7–9] and adult patients [10,11], and on a post hoc analysis of a randomized controlled trial in sepsis that suggested a benefit of anakinra in selected patients [12]. The recent SAVE-MORE study confirmed the efficacy and safety of anakinra in patients with features of SARS-CoV2-induced sHLH [13], providing an encouraging and reassuring signal in sHLH, even due to infection.

2. Materials and Methods

We conducted a multicentric retrospective study in two University hospitals (Lyon and Rouen, France) to evaluate the efficacy and safety of anakinra in sHLH of any etiology. We searched our local database from January 2012 to April 2022 with the terms “HLH”, “macrophage activation syndrome” and “anakinra”, and performed a call for observation. Patients who had sHLH defined by an H score > 169 (169 being the best cut-off value for H Score in the study of development and validation of the H score [14]), a clinician-confirmed diagnosis and who received anakinra in this setting were included.

Clinical, demographic and laboratory data were analysed and descriptive statistics computed for each variable. Categorical variables are presented as numbers and proportions, and continuous variables as medians with interquartile ranges [IQR]. Groups were compared using the Fisher’s exact test (for categorical variables) or the Wilcoxon test (for continuous variables); \( p < 0.05 \) was considered significant. We used Microsoft Excel version 2019 (Redmond, WA, USA) for all analyses.

All patient data were collected retrospectively. This study was conducted in compliance with good clinical practices and the principles of the Declaration of Helsinki. In accordance with local laws, formal approval from an ethics committee was not required for this type of retrospective study.

3. Results

Among 21 patients, with a median age of 45 years [IQR, 33–58], 8 were women and 13 were men. There were three children. The median time from onset of sHLH symptoms to sHLH diagnosis was 12 days [IQR, 8–15]. At least one sHLH-triggering condition was identified in all cases: six rheumatic diseases (three Still’s disease and three systemic-onset juvenile idiopathic arthritis), five malignancies (two lymphomas, two myelodysplastic syndromes and one urothelial carcinoma) and twelve infections (four tuberculosis, three bacterial infections, two fungal infections and three viral infections).

sHLH was the inaugural manifestation of the predisposing disease in 15 patients (71%). The main symptoms were fever (\( n = 21 \)), hepatosplenomegaly (\( n = 15 \)), lymphadenopathy (\( n = 12 \)) and serositis (\( n = 9 \)). The median ferritin level was 13,835 ng/mL and the median H score was 244, corresponding to a median HLH probability of 99.1%. A bone marrow
aspiration was performed in all patients, and retrieved hemophagocytosis in 16 (76%) cases (Table 1).

Table 1. Clinical and laboratory findings in 21 patients with secondary HLH.

| Number of Patients (%) or Median [IQR] |
|--------------------------------------|
| Gender (male) 13 (62%)               |
| Age (years) 45.0 [33.0–58.0]         |
| Time from first symptoms to diagnosis of HLH (days) 12.0 [8.0–15.0] |
| Underlying condition                  |
| Known underlying immunodepression 8 (38%) |
| Malignancy 5 (24%)                   |
| Infection 12 (57%)                   |
| Rheumatic disease (AOSD or sJIA) 6 (29%) |
| Medication 1 (4.8%)                  |
| Unknown 1 (4.8%)                     |
| Mean number of underlying conditions 2 (1–2) |
| Fever 21 (100%)                      |
| Rash 6 (29%)                         |
| Arthralgia/Arthritis 6 (29%)         |
| Hepatosplenomegaly 15 (71%)          |
| Lymphadenopathy 12 (57%)             |
| Serositis 9 (43%)                    |
| Neurological symptoms 5 (24%)        |
| Intensive care unit admission 10 (48%) |
| White blood cells (G/L) (4.0–10.0) * 4.3 [3.1–14.4] |
| Neutrophils (G/L) (1.8–7.5) * 3.3 [1.9–11.2] |
| Haemoglobin (g/dL) (13.0–17.0) * 7.8 [7.2–7.9] |
| Platelets (G/L) (150.0–388.0) * 71.0 [40.0–141.0] |
| Ferritin (µg/L) (20.0–336.0) * 13,835.0 [6072.5–27,001.0] |
| Glycosylated ferritin (% of total ferritin) 15.0 [12.5–19.8] |
| Triglycerides (mmol/L) (0.4–1.7) * 3.5 [3.0–4.5] |
| Fibrinogen (g/L) (2.0–4.0) * 2.4 [1.5–4.5] |
| Aspartate aminotransferase (U/L) (15.0–37.0) * 167.0 [58.0–345.0] |
| Lactate dehydrogenase (U/L) (87.0–241.0) * 635.0 [314.0–1263.0] |
| CRP (mg/dL) (0.0–0.8) * 116.0 [90.4–155.5] |
| Hemophagocytosis images on bone marrow aspirates 16 (76.2) |

AOSD: adult-onset Still’s disease; HLH: hemophagocytic lymphohistiocytosis; sJIA: systemic-onset juvenile idiopathic arthritis; * Numbers in parenthesis are the reference values; IQR: interquartile range.

Anakinra was used as first-line treatment for sHLH in 10 patients. In six patients (five with infection, one with Hodgkin’s lymphoma), anakinra was administered as monotherapy without corticosteroids. None of these six patients required a new line of treatment for sHLH; only one patient was switched to oral corticosteroids to facilitate drug intake. In four patients (two with rheumatic disease, one with Hodgkin’s lymphoma and one with
infection), anakinra was combined with corticosteroids. None of these patients warranted a new line of treatment. Anakinra was used as a second-line treatment after failure of corticosteroid therapy alone in seven patients (two with infection, two with myelodysplastic syndrome, two with rheumatic disease and one with graft rejection). None of these seven patients required a new line of treatment for sHLH. Anakinra was prescribed as a third-line treatment in two cases (one with rheumatic disease, one with infection), after failure of polyvalent immunoglobulin and then steroid therapy alone. In patient 15, who had juvenile idiopathic arthritis and primary parvovirus B19 infection, a fourth line of treatment with ciclosporine was required after failure of anakinra. Anakinra was used as a fourth-line therapy in patient 3 who presented sHLH in the context of Crohn’s disease treated with azathioprine, after the use of corticosteroids, polyvalent immunoglobulin and etoposide. Anakinra was not effective in this patient. Finally, anakinra was used as fifth-line therapy in patient 9 with Still’s disease, without the need for a new line of therapy (Table 2, Supplementary Data S1).

The drug was always delivered subcutaneously, at dosages of 100 mg/day (n = 14), 200 mg/day (n = 5), or 2–5 mg/kg/day in children (n = 2).

According to the clinician, anakinra was effective in 19 patients (90.5%). In three cases, the dose of anakinra had to be doubled to achieve remission. Fever resolved in 19 patients (90.5%) within a median of 1.0 day [IQR, 1–2]. At the Day 7 assessment, the mean CRP concentration decreased significantly (p < 0.001), as did the mean ferritin (p = 0.011), but there was no statistical difference in cytopenia (Table 3).

Fifteen patients achieved a CRP < 10 mg/L, within a mean delay of 12 days [IQR, 7.5–32.0]. The average duration of hospitalization was 16 days [IQR, 10–32] after starting anakinra. The median duration of treatment with anakinra was 21 days [IQR, 13–19], with shorter durations for malignancies or infections than for Still’s disease (median, 17 vs. 195 days, p = 0.016). At last follow-up, two patients with rheumatic diseases were still receiving anakinra after two and five years, respectively.

Anakinra was generally well tolerated; five patients (23.8%) had side effects: two injection-site pain, one erysipelas, one pneumonia, and one allergic reaction. Treatment discontinuation was required in three cases.

During a median follow-up of 10 months [IQR, 4.0–22.0], three patients died: two deaths were due to the underlying hematologic malignancies and one to an uncontrolled sHLH (Patient 3). Four patients experienced a recurrence of sHLH. All cases were controlled either by increasing the dosage of anakinra (n = 4), or by combining CS (n = 1), CSA (n = 1), or azacytidine (n = 1; Table 3, Supplementary Data S1).
Table 2. Patients’ characteristics and outcome.

| Patient | Age | Sex | Predisposing and Precipitating Factors | H Score | sHLH Treatment and Line Number | Anakinra Efficacy * | Anakinra Duration (Days) | CTC Duration (Days) | Live Status at Last Visit | Outcome (or Cause of Death) |
|---------|-----|-----|----------------------------------------|---------|-------------------------------|--------------------|------------------------|---------------------|--------------------------|----------------------------|
| 1       | 38  | M   | Tuberculosis, COVID-19                 | 309     | 1. ANA                        | Yes                | 13                     | 0                   | Alive                    | Recurrence of IRIS without criterion of sHLH at 1 month. |
| 2       | 33  | M   | HIV, tuberculosis, IRIS, CMV and EBV replication | 224     | 1. CTC, 2. ANA                 | Yes                | 67                     | 90                  | Alive                    | Favourable clinical evolution and good tolerance of antibiotic therapy. Continued tuberculosis treatment during 9 months. |
| 3       | 73  | F   | Crohn’s disease treated with azathioprine | 299     | 1. CTC, 2. VP16, 3. IVIG, 4. ANA, 5. HLH-2004 | No                 | 13                     | 120                 | Deceased                 | Uncontrolled sHLH of unknow origin. |
| 4       | 66  | M   | MDS                                    | 214     | 1. CTC, 2. ANA                 | Yes                | 20                     | 14                  | Deceased                 | sHLH recurrence after decrease of anakinra dosage, good evolution after re-increasing anakinra to 400 mg/d and chemotherapy with azacytidine, but refusal to continue treatment. |
| 5       | 51  | M   | HL, EBV replication                    | 262     | 1. ANA + CTC                   | Yes                | 5                      | 7                   | Alive                    | Initiation of chemotherapy 7 days after sHLH diagnosis |
| 6       | 64  | M   | MDS                                    | 218     | 1. CTC, 2. ANA                 | Yes                | 90                     | 150                 | Deceased                 | Initial response to ANA, followed by azacytidine initiation with good efficacy. MDS recurrence with Sweet’s syndrome 3 years later. |
| 7       | 20  | M   | IJA, tocilizumab                       | 210     | 1. CTC, 2. ANA                 | Yes                | ###                    | ###                 | Alive                    | Slow normalization of biological parameters, long-term ANA continuation without recurrence of sHLH |
| 8       | 17  | F   | Still’s disease, Parvovirus B19        | 230     | 1. ANA + CTC                   | Yes                | 180                    | 1420                | Alive                    | ANA efficacy but sHLH recurrence at 1 then at 2 months, controlled with ANA increase and CSA. Recurrent skin eruption under ANA, switch to tocilizumab. |
| Patient | Age | Sex | Predisposing and Precipitating Factors | H Score | sHLH Treatment and Line Number | Anakinra Efficacy * | Anakinra Duration (Days) | CTC Duration (Days) | Live Status at Last Visit | Outcome (or Cause of Death) |
|---------|-----|-----|---------------------------------------|---------|--------------------------------|---------------------|-------------------------|----------------------|--------------------------|-----------------------------|
| 9       | 41  | F   | Still’s disease                        | 224     | 1. CTC, 2. VP16, 3. CSA, 4. VP16, 5. ANA | Yes                 | 660                     | 660                  | Alive                    | Two resolved sHLH recurrences after increasing the anakinra dosage to 200 mg/d |
| 10      | 61  | M   | Infection (Rickettsia tiphly)          | 232     | 1. ANA                           | Yes                 | 5                       | 0                    | Alive                    | Resolution of sHLH under anakinra then treatment with doxycycline 21 days for an infection with *Rickettsia tiphly*. No recurrence. |
| 11      | 45  | F   | Still’s disease                        | 279     | 1. CTC, 2. ANA                   | Yes                 | 14                      | 610                  | Alive                    | Good efficacy of anakinra but pain at the injection site. Switch to tocilizumab with new cutaneous intolerance. Initiation of methotrexate allowing complete withdrawal of CTC. |
| 12      | 51  | M   | Graft rejection                        | 317     | 1. CTC, 2. ANA                   | Yes                 | 21                      | 130                  | Alive                    | Favourable evolution of inflammation and liver disease under anakinra. Discontinuation of anakinra and continuation of corticosteroid alone after 21 days due to erysipelas. |
| 13      | 35  | F   | Tuberculosis                           | 294     | 1. ANA, 2. CTC                   | Yes                 | 45                      | 180                  | Alive                    | Efficacy of anakinra pending liver biopsy results. Then, anti-tuberculosis therapy and CTC. |
| 14      | 28  | F   | Kidney transplant, Tuberculosis, IRIS  | 267     | 1. CTC, 2. ANA                   | Yes                 | 120                     | 28                   | Alive                    | IRIS resistant to CTC. Dramatic efficacy of anakinra, maintained during the first 4 months of anti-tuberculosis treatment. |
| 15      | 6   | M   | JIA, Parvovirus primoinfection         | 254     | 1. IVIG, 2. CTC, 3. ANA, 4. CSA + IVIG + CTC | No                  | 210                     | 90                   | Alive                    | Failure of IVIG, CTC and then anakinra. sHLH finally suppressed by the association of CTC, CSA and IVIG. Resumption of anakinra as background treatment. |
Table 2. Cont.

| Patient | Age | Sex | Predisposing and Precipitating Factors | H Score | sHLH Treatment and Line Number | Anakinra Efficacy * | Anakinra Duration (Days) | CTC Duration (Days) | Live Status at Last Visit | Outcome (or Cause of Death) |
|---------|-----|-----|----------------------------------------|---------|--------------------------------|-------------------|--------------------------|----------------------|---------------------------|----------------------------|
| 16      | 4   | F   | JIA                                    | 244     | 1. ANA + CTC                   | Yes               | 60                       | 300                  | Alive                     | Good efficacy of ANA after increasing dosage, switch to canakinumab but relapse requiring a new switch to tocilizumab and then to baricitinib. |
| 17      | 55  | F   | HL                                     | 252     | 1. ANA                         | Yes               | 6                       | 0                    | Alive                     | Dramatic response to anakinra allowing diagnostic investigations of the malignant hemopathy without CTC. Initiation of chemotherapy thereafter. |
| 18      | 58  | M   | Post-infection (bacteriemia)           | 187     | 1. ANA + CTC                   | Yes               | 17                       | 7                    | Alive                     | sHLH of undetermined aetiology; *Streptococcus Suis* bacteriemia with arthritis of the right shoulder. Favourable evolution without recurrence. |
| 19      | 35  | F   | Infection                              | 225     | 1. ANA                         | Yes               | 8                        | 0                    | Alive                     | Cardiogenic shock on stress heart disease and sHLH due to ENT infection. Favourable evolution of sHLH under anakinra alone, no recurrence. |
| 20      | 58  | M   | Infection (Knee prosthesis) and medication | 246   | 1. IVIG, 2. CTC, 3. ANA       | Yes               | 14                       | 17                   | Alive                     | Cardiogenic shock complicating knee prosthesis infection with *Staphylococcus aureus* and *Candida krusei*. Need for ECMO. Favourable evolution under antibiotics/antifungal therapy and ANA. |
| 21      | 77  | M   | Infection, urothelial carcinoma        | 208     | 1. ANA                         | Yes               | 14                       | 0                    | Alive                     | Favourable evolution under anakinra as monotherapy of sHLH due to multiple intra-abdominal *Candida* collections, in the setting of an underlying urothelial cancer |

ANA: anakinra; CSA: ciclosporine; CTC: corticosteroids; HL: Hodgkin’s lymphoma; HLH-2004: etoposide-dexamethasone-CSA; IRIS: Immune reconstitution inflammatory syndrome; MDS: myelodysplastic syndrome; JIA: juvenile idiopathic arthritis; VP16: etoposide. * As reported by the treating physician.
Table 3. Evolution of clinical and biological features under anakinra.

| Parameters (n *) | Day 0 | Day 7 | p-Value |
|-----------------|-------|-------|---------|
| Fever (n = 18)  | 16 (88.9%) | 3 (16.7%) | 0.021 |
| CRP (n = 15)    | 116   | 35.1  | <0.001 |
| Ferritin (µg/L) (n = 15) | 10,044 | 2014 | 0.011 |
| Triglycerides (mmol/L) (n = 5) | 3.7 | 2.7 | 1.000 |
| Aspartate aminotransferase (U/L) (n = 19) | 130 | 48 | 0.025 |
| Haemoglobin (g/dL) (n = 20) | 8.9 | 9.1 | 0.946 |
| White blood cells (G/L) (n = 20) | 6.7 | 5.1 | 1.000 |
| Platelets (G/L) (n = 20) | 68 | 118.5 | 0.417 |

* Number of patients with data available at D0 and D7 included in the analysis. Statistically significant p values (<0.05) are shown in bold font.

4. Discussion

In this study, the use of anakinra in 21 patients with sHLH of various aetiologies was associated with a favourable outcome in 19 patients (90.5%). The resolution of symptoms was rapid and biological inflammation improved within the first week. However, cytopenia took longer to improve (with or without underlying hemopathy). Apart from injection-site pain, side effects occurred in <15% of cases in immunocompromised subjects. Anakinra was used without corticosteroids in five patients, which allowed us to carry out the diagnostic investigations without fear of negative histological samples.

Unlike some other HLH-specific treatments, anakinra seems to have a satisfactory safety profile and could be preferred to etoposide, at least as a therapeutic test during the first 24–72 h, due to a lower septic risk and the absence of haematological toxicity, or to ciclosporine, due to its risk of neurological toxicity [4]. In cases of EBV-associated sHLH or multi-visceral failure, etoposide remains a first-line option. However, it is possible that anakinra can be used in addition to etoposide, without significantly increasing the infectious risk, to achieve rapid control of a deleterious cytokine storm. Moreover, its short duration of action makes it more manageable than other specific treatments or biotherapies such as IL-6 inhibitors.

Limitations of this study include the small number of patients and its retrospective nature in relation to the low prevalence of HLH. The small sample size prevented deeper analyses, such as the search of predictors of response. Furthermore, judging the efficacy of anakinra in sHLH is made more difficult by the fact that it is a disease that is itself associated with many different pathological conditions that warrant specific treatment, and as anakinra is not currently approved for use in this indication, the administration regimens are left to the discretion of the clinician. However, our data are consistent with the efficacy of anakinra and add original cases of anakinra use in real life to the literature, which will inform future systematic reviews and are useful until a prospective work can provide precise answers.

5. Conclusions

We report encouraging data on the efficacy and safety of anakinra in the control of sHLH of various causes. Prospective studies are needed to fully confirm this efficacy and to precisely define the place of this drug in the management of sHLH.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11195799/s1; Supplementary Data S1: Case description.
Author Contributions: All co-authors have reviewed the manuscript and have contributed in a substantive and intellectual manner to the work described. A.B., E.W., Q.R., M.G.-V., P.S., T.P., S.D.G. and Y.J. followed the patients; C.B. collected the data; C.B. and Y.J. drafted the manuscript and all co-authors revised it critically for important intellectual content. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Informed Consent Statement: According to French law (No. 2004-806, 9 August 2004), and because the data were collected retrospectively, and patient management was not modified, this study did not require informed consent.

Data Availability Statement: All the data are provided within the text or as Supplementary Materials.

Conflicts of Interest: Y.J. and M.G.-V. have received fees from SOBI (congress, advisory board).

References
1. Hayden, A.; Park, S.; Giustini, D.; Lee, A.Y.Y.; Chen, L.Y.C. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood Rev. 2016, 30, 411–420. [CrossRef] [PubMed]
2. Grom, A.A.; Horne, A.; De Benedetti, F. Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 2016, 12, 259–268. [CrossRef] [PubMed]
3. Henter, J.-I.; Horne, A.; Arico, M.; Egeler, R.M.; Filipovich, A.H.; Imashuku, S.; Ladisch, S.; McClain, K.; Webb, D.; Winiariski, J.; et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2007, 48, 124–131. [CrossRef] [PubMed]
4. Carter, S.J.; Tattersall, R.S.; Ramanan, A.V. Macrophage activation syndrome in adults: Recent advances in pathophysiology, diagnosis and treatment. Rheumatology 2019, 58, 5–17. [CrossRef] [PubMed]
5. Bauchmuller, K.; Manson, J.J.; Tattersall, R.; Brown, M.; McNamara, C.; Singer, M.; Brett, S.J. Haemophagocytic lymphohistiocytosis in adult critical care. J. Intensive Care Soc. 2020, 21, 256–268. [CrossRef] [PubMed]
6. NHS England. Anakinra for Haemophagocytic Lymphohistiocytosis for Adults and Children in All Ages n.d. Available online: https://www.england.nhs.uk/publication/anakinra-for-haemophagocytic-lymphohistiocytosis-for-adults-and-children-in-all-ages/ (accessed on 4 February 2022).
7. Eloseily, E.M.; Weiser, P.; Crayne, C.B.; Haines, H.; Mannion, M.L.; Stoll, M.L.; Beukelman, T.; Atkinson, T.P.; Cron, R.Q. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2020, 72, 326–334. [CrossRef] [PubMed]
8. Gregory, J.; Greenberg, J.; Basu, S. Outcomes Analysis of Children Diagnosed with Hemophagocytic Lymphohistiocytosis in the PICU. Pediatr. Crit. Care Med. 2019, 20, e185–e190. [CrossRef] [PubMed]
9. Simmez, H.E.; Demir, S.; Bilginer, Y.; Ozen, S. Anakinra treatment in macrophage activation syndrome: A single center experience and systematic review of literature. Clin. Rheumatol. 2018, 37, 3329–3335. [CrossRef] [PubMed]
10. Kumar, B.; Aleem, S.; Saleh, H.; Petts, J.; Ballas, Z.K. A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults. J. Clin. Immunol. 2017, 37, 638–643. [CrossRef] [PubMed]
11. Wohlfarth, P.; Agis, H.; Gualdoni, G.A.; Weber, J.; Staudinger, T.; Schellongowski, P.; Robak, O. Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients with Hemophagocytic Lymphohistiocytosis. J. Intensive Care Med. 2019, 34, 723–731. [CrossRef] [PubMed]
12. Shakoory, B.; Carcillo, J.A.; Chatham, W.W.; Amdur, R.L.; Zhao, H.; Dinarello, C.A.; Cron, R.Q.; Opal, S.M. Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit. Care Med. 2016, 44, 275–281. [CrossRef] [PubMed]
13. Kyriazopoulou, E.; Panagopoulos, P.; Metallidis, S.; Dalekos, G.N.; Poulakou, G.; Gatselis, N.; Karakike, E.; Saridaki, M.; Loli, G.; Stefos, A.; et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 2021, 10, e66125. [CrossRef] [PubMed]
14. Fardet, L.; Galicier, L.; Lambotte, O.; Marzac, C.; Aumont, C.; Chahwan, D.; Coppo, P.; Heijblum, G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014, 66, 2613–2620. [CrossRef] [PubMed]